THIS WEBSITE USES cookies.
BY ACCESSING THIS WEBSITE, YOU EXPRESS YOUR CONSENT TO THE USE OF COOKIES IN ACCORDANCE
WITH THE TERMS OF THE Cookies Policy. IF YOU DO NOT CONSENT TO THE USE OF cookieS,
PLEASE ADJUST YOUR BROWSER SETTINGS ACCORDINGLY, OR DO NOT CONTINUE BROWSING THE SITE.

SEARCH:
  •   The Value
        of QUALITY
  •   Favouring
    SCIENTIFIC PROGRESS
  • The Value
    of RESEARCH
  • Research
    Tradition
  • Attention and
        Responsibility
    TOWARDS OF TERRITORY

sigma-tau is one of the most important Italian pharmaceutical groups, with a major presence also on the international stage. For more than half a century the company has been active in promoting the quality of life of man and his health.
sigma-tau is present today in the most advanced research sectors, maintaining constant relations with scientific institutions with a world-wide reputation in the development of joint projects and in the implementation of original and innovative research programs.
These results are the fruit of substantial, ongoing investment in research in the field of pharmaceutical innovation and stem not only from the efforts made to produce new products but also from the success of the company’s consolidated products.
Bearing witness to sigma-tau’s achievements are not only the principles and values that inspire our efforts - innovation, dialogue and transparency, ethics, sustainability - but also the facts that have made sigma-tau a leading company in the research, manufacture and marketing of drugs.
In pursuit of its important mission of guaranteeing health and a better quality of life for people world-wide, sigma-tau has constantly combined economic expansion with the creation of value for society and the environment. Research, innovation and business must, in fact, be firmly linked to the social dimension - essential components of an entrepreneurial culture oriented towards responsible, sustainable development, fully respecting the needs of the individual, of society and of the environment.

 
 

13.04.2015
From: La Repubblica - Affari & Finanza

Risiko farmaceutico italiano boom di fusioni e acquisizioni e stop alle delocalizzazioni
30.03.2015
From: La Repubblica - Affari & Finanza

Acquisizioni, non solo prede. Buzzi, De Agostini, SigmaTau a comprare sono gli italiani
30.03.2015
From: CorrierEconomia

Stefano Golinelli: per la chimica italiana è il tempo delle rivincite

05.03.2015

LAUNCH OF THE INDUSTRIAL PARTNERSHIP IN THE PHARMA BUSINESS BETWEEN ALFA WASSERMANN AND SIGMA-TAU: SETTING UP A LEADING ITALIAN PHARMACEUTICAL GROUP
24.10.2014

UNA SOLUZIONE “SALVAVITA” PER CHI HA AVUTO UN INFARTO ‐ CONFERMATI I RISULTATI DEL GISSI   PREVENZIONE CON UNO STUDIO NEL MONDO REALE
11.12.2013

L’AIFA introduce la nota 94 per i farmaci PUFA N‐3 (Esteri Etilici di acidi grassi polinsaturi della serie Omega-3). Tornano prescrivibili a carico del SSN per i pazienti con sindrome coronarica acuta.

 
 
 
 
2015© sigma-tau s.p.a. | VAT no. 00885531004